Molecular genetic profile of 620 patients with acute myeloid leukemia, assessment of the impact of mutations on prognosis

Acute myeloid leukemia (AML) is a complex, genetically variable, dynamic disease. An important task at the moment is to create a new system for classifying patients into risk groups, based both on the results of cytogenetic studies and on the influence of additional molecular alterations and their combinations on the prognosis. An extensive study of molecular genetic markers in patients with AML will allow the most thorough investigation of the pathogenesis of the disease at different stages (debut, remission, relapse), to predict possible risks and include targeted drugs in the therapy protocol, and will serve as an additional argument in choosing candidates for allogenic hemopoietic stem cells (allo- THSC).